Joshua B Wallach

Joshua B Wallach

Auto-generated profile, based on publicly available information

Joshua B Wallach

Dept. of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CNClaire Naylor
Claire Naylor
GPGareth A Prosser
Gareth A Prosser
TBTracy Bayliss
Tracy Bayliss
LBLila Berle
Lila Berle
JWJoshua B Wallach
Joshua B Wallach
LCLaura A T Cleghorn
Laura A T Cleghorn
Globally, Mycobacterium tuberculosis remains a significant disease burden. Although effective treatment regimens exist, drug resistance continues to emerge. This clinical resistance, combined with side effects and protracted treatment times from the current front-line therapies, means there is a need to identify novel agents to combat this disease. Here we report on a new chemical series, identified by whole-cell phenotypic growth inhibition screening that demonstrates significant activity across multiple media. Mode of action studies indicate that this series targets the same biological pathway as Ethambutol (EMB), a drug used in the current frontline treatment of tuberculosis. Screening selected analogues against clinical isolates, resistant to EMB, demonstrated differential sensitivity both across the molecules and against the different specific resistant mutations. The data obtained suggests that this series has potential to be developed into a viable, alternative to EMB. TOC figure: